TNYA Tenaya Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TNYA matters now
Tenaya Therapeutics, Inc. (TNYA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.87 with +2.40% on the session and $145.0M in market capitalization; recent performance reads 1-month -7.23% and YTD +2.68%.
The latest financial table shown here is Q1 2026, with revenue of $225.0K, net income of $-19.3M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -53.1%.
The latest indexable market news headline is "Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes Burroughs Amy L. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.05
P/S
540.98
EV/EBITDA
-0.68
DCF Value
$0.57
FCF Yield
-53.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
144.9%
Operating Margin
-38159.1%
Net Margin
-36891.1%
ROE
-80.6%
ROA
-61.5%
ROIC
-70.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $225.0K | $-19.3M | $-0.09 |
| Q4 2025 | $0.00 | $-20.2M | $-0.12 |
| FY 2025 | $0.00 | $-90.6M | $-0.59 |
| Q3 2025 | $0.00 | $-20.3M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.82
Tenaya Therapeutics, Inc. is a U.S.-based biotechnology firm focused on unearthing, advancing, and providing novel treatments for various cardiovascular diseases. The company harnesses advanced scientific platforms, including cellular regeneration, gene therapy, and precision medicine, to develop its therapeutic candidates. Among its primary therapeutic initiatives is TN-201, an adeno-associated virus (AAV)-based gene therapy engineered to tackle genetic hypertrophic cardiomyopathy (gHCM) arising from haploinsufficient mutations in the myosin binding protein C3 (MYBPC3) gene. A prominent compound in its pipeline is TN-301, a small molecule histone deacetylase 6 inhibitor (HDAC6i) slated for use in both heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Tenaya is also progressing TN-401, another AAV-based gene therapy aimed at genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) resulting from specific plakophilin 2 (PKP2) gene anomalies. Further, an AAV gene therapy is under development that seeks to introduce the dwarf open reading frame (DWORF) gene into cardiac tissue to address dilated cardiomyopathy (DCM). Rounding out its innovative portfolio, the 'Reprogramming program' employs an AAV-driven approach for cardiac regeneration, striving to replenish heart cells lost in patients who experience heart failure subsequent to a prior myocardial infarction. Founded in 2016, Tenaya operates from its base in South San Francisco, California.